Literature DB >> 35486871

Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions that Promotes Disease Persistence.

Bethany D Batson1,2, Bryan T Zorn1,3, Giorgia Radicioni1,2, Stephanie S Livengood1,2, Tadahiro Kumagai4, Hong Dang1, Agathe Ceppe1, Phillip W Clapp1, Michael Tunney5, J Stuart Elborn5, Noel G McElvaney6, Marianne S Muhlebach1, Richard C Boucher1, Michael Tiemeyer4, Matthew C Wolfgang1,3, Mehmet Kesimer1,2.   

Abstract

The dynamics describing the vicious cycle characteristic of cystic fibrosis (CF) lung disease, initiated by stagnant mucus and perpetuated by infection and inflammation, remain unclear. Here we determine the effect of the CF airway milieu, with persistent mucoobstruction, resident pathogens, and inflammation, on the mucin quantity and quality that govern lung disease pathogenesis and progression. The concentrations of MUC5AC and MUC5B were measured and characterized in sputum samples from subjects with CF (N = 44) and healthy subjects (N = 29) with respect to their macromolecular properties, degree of proteolysis, and glycomics diversity. These parameters were related to quantitative microbiome and clinical data. MUC5AC and MUC5B concentrations were elevated, 30- and 8-fold, respectively, in CF as compared with control sputum. Mucin parameters did not correlate with hypertonic saline, inhaled corticosteroids, or antibiotics use. No differences in mucin parameters were detected at baseline versus during exacerbations. Mucin concentrations significantly correlated with the age and sputum human neutrophil elastase activity. Although significantly more proteolytic cleavages were detected in CF mucins, their macromolecular properties (e.g., size and molecular weight) were not significantly different than control mucins, likely reflecting the role of S-S bonds in maintaining multimeric structures. No evidence of giant mucin macromolecule reflecting oxidative stress-induced cross-linking was found. Mucin glycomic analysis revealed significantly more sialylated glycans in CF, and the total abundance of nonsulfated O-glycans correlated with the relative abundance of pathogens. Collectively, the interaction of mucins, pathogens, epithelium, and inflammatory cells promotes proteomic and glycomic changes that reflect a persistent mucoobstructive, infectious, and inflammatory state.

Entities:  

Keywords:  cystic fibrosis; inflammation; microbiome; mucins; mucus obstruction

Mesh:

Substances:

Year:  2022        PMID: 35486871      PMCID: PMC9348562          DOI: 10.1165/rcmb.2021-0359OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   7.748


  49 in total

Review 1.  Airway surface dehydration in cystic fibrosis: pathogenesis and therapy.

Authors:  Richard C Boucher
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

2.  Dynamic developmental elaboration of N-linked glycan complexity in the Drosophila melanogaster embryo.

Authors:  Kazuhiro Aoki; Mindy Perlman; Jae-Min Lim; Rebecca Cantu; Lance Wells; Michael Tiemeyer
Journal:  J Biol Chem       Date:  2007-01-29       Impact factor: 5.157

3.  Cystic Fibrosis Sputum Rheology Correlates With Both Acute and Longitudinal Changes in Lung Function.

Authors:  Jonathan T Ma; Christina Tang; Le Kang; Judith A Voynow; Bruce K Rubin
Journal:  Chest       Date:  2018-03-17       Impact factor: 9.410

4.  Glycosylation of sputum mucins is altered in cystic fibrosis patients.

Authors:  Benjamin L Schulz; Andrew J Sloane; Leanne J Robinson; Sindhu S Prasad; Robyn A Lindner; Michael Robinson; Peter T Bye; Dennis W Nielson; Jenny L Harry; Nicolle H Packer; Niclas G Karlsson
Journal:  Glycobiology       Date:  2007-03-28       Impact factor: 4.313

5.  Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.

Authors:  Giorgia Radicioni; Agathe Ceppe; Amina A Ford; Neil E Alexis; R Graham Barr; Eugene R Bleecker; Stephanie A Christenson; Christopher B Cooper; MeiLan K Han; Nadia N Hansel; Annette T Hastie; Eric A Hoffman; Richard E Kanner; Fernando J Martinez; Esin Ozkan; Robert Paine; Prescott G Woodruff; Wanda K O'Neal; Richard C Boucher; Mehmet Kesimer
Journal:  Lancet Respir Med       Date:  2021-05-28       Impact factor: 102.642

6.  An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases.

Authors:  Camille Ehre; Zachary L Rushton; Boya Wang; Lauren N Hothem; Cameron B Morrison; Nicholas C Fontana; Matthew R Markovetz; Martial F Delion; Takafumi Kato; Diane Villalon; William R Thelin; Charles R Esther; David B Hill; Barbara R Grubb; Alessandra Livraghi-Butrico; Scott H Donaldson; Richard C Boucher
Journal:  Am J Respir Crit Care Med       Date:  2019-01-15       Impact factor: 30.528

7.  Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum.

Authors:  David J Serisier; Mary P Carroll; Janis K Shute; Simon A Young
Journal:  Respir Res       Date:  2009-07-06

Review 8.  Chloride channels of intracellular organelles and their potential role in cystic fibrosis.

Authors:  Q al-Awqati; J Barasch; D Landry
Journal:  J Exp Biol       Date:  1992-11       Impact factor: 3.312

9.  A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease.

Authors:  David B Hill; Paula A Vasquez; John Mellnik; Scott A McKinley; Aaron Vose; Frank Mu; Ashley G Henderson; Scott H Donaldson; Neil E Alexis; Richard C Boucher; M Gregory Forest
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

10.  MIRAGE: the minimum information required for a glycomics experiment.

Authors:  William S York; Sanjay Agravat; Kiyoko F Aoki-Kinoshita; Ryan McBride; Matthew P Campbell; Catherine E Costello; Anne Dell; Ten Feizi; Stuart M Haslam; Niclas Karlsson; Kay-Hooi Khoo; Daniel Kolarich; Yan Liu; Milos Novotny; Nicolle H Packer; James C Paulson; Erdmann Rapp; Rene Ranzinger; Pauline M Rudd; David F Smith; Weston B Struwe; Michael Tiemeyer; Lance Wells; Joseph Zaia; Carsten Kettner
Journal:  Glycobiology       Date:  2014-03-20       Impact factor: 4.313

View more
  1 in total

1.  Infection and Inflammation MUC up the Cystic Fibrosis Airway.

Authors:  Jonathan Ma
Journal:  Am J Respir Cell Mol Biol       Date:  2022-08       Impact factor: 7.748

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.